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Abstract
There are limited data describing the functional characteristics of HIV-1 specific antibodies in breast milk (BM) and their role
in breastfeeding transmission. The ability of BM antibodies to bind HIV-1 envelope, neutralize heterologous and autologous
viruses and direct antibody-dependent cell cytotoxicity (ADCC) were analyzed in BM and plasma obtained soon after
delivery from 10 non-transmitting and 9 transmitting women with high systemic viral loads and plasma neutralizing
antibodies (NAbs). Because subtype A is the dominant subtype in this cohort, a subtype A envelope variant that was
sensitive to plasma NAbs was used to assess the different antibody activities. We found that NAbs against the subtype A
heterologous virus and/or the woman’s autologous viruses were rare in IgG and IgA purified from breast milk supernatant
(BMS) – only 4 of 19 women had any detectable NAb activity against either virus. Detected NAbs were of low potency
(median IC50 value of 10 versus 647 for the corresponding plasma) and were not associated with infant infection (p=0.58).
The low NAb activity in BMS versus plasma was reflected in binding antibody levels: HIV-1 envelope specific IgG titers were
2.2 log10 lower (compared to 0.59 log10 lower for IgA) in BMS versus plasma. In contrast, antibodies capable of ADCC were
common and could be detected in the BMS from all 19 women. BMS envelope-specific IgG titers were associated with both
detection of IgG NAbs (p=0.0001)and BMS ADCC activity (p=0.014). Importantly, BMS ADCC capacity was inversely
associated with infant infection risk (p=0.039). Our findings indicate that BMS has low levels of envelope specific IgG and
IgA with limited neutralizing activity. However, this small study of women with high plasma viral loads suggests that
breastmilk ADCC activity is a correlate of transmission that may impact infant infection risk.
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Introduction
Breast milk (BM) can be a vehicle for transmission of various
pathogens, but the risk of infant infection is balanced by the
potential clinical benefit of BM, which provides significant passive
immunity and protection against many infectious agents [1–4]. In
the case of HIV-1, exposure to virus through breastfeeding
accounts for almost half of the 30–40% of vertical transmissions
that occur in untreated, breastfed infants of HIV-1 positive women
[5–7]. Replacement feeding, avoidance of breastfeeding and
reduced BM exposure by early weaning can significantly reduce
BM transmission, however, these interventions have been associ-
ated with significant increase in infant morbidity and mortality [8–
13]. Additionally, HIV-1 infected as well as exposed uninfected
infants who do not breast feed have been shown to exhibit stunted
growth [14,15]. These observations highlight the challenges facing
HIV-1 infected women in sub- Saharan Africa where prolonged
breastfeeding could lead to HIV-1 transmission but no breast
feeding could increase the risk of morbidity and mortality resulting
in a diluted benefit of HIV-1 free survival [16–18]. Consequently,
greater understanding of BM protective factors in HIV-1 infection
may open promising new ways to make breastfeeding safe for
infants born toHIV-1 infected women.
Approximately 15–20% of infants born to all HIV-1+ mothers
in chronic infection acquireHIV-1 through BM [6,7,19,20]. This
relatively low infection rate despite continued exposure suggests
that either BM infectivity is low or that antiviral factors in BM may
play a role in modulating transmission and/or acquisition of HIV-
1 via the oral mucosa. Indeed, antiviral innate immune factors
present in BM such as alpha defensins, bile salt-stimulated lipase,
lactoferrin, and mucins have all been associated with modulating
the risk of BM transmission [21–23]. BM is also composed of both
innate and activated adaptive immune cells, presumably derived
from other mucosal sites such as the gut associated lymphoid
tissue. Indeed, HIV-1 specific CD8 T cells and B cells have been
reported in BM [24–26], but to date there have been no published
studies that have explored the association between the functional
immune responses in BM and risk ofHIV-1 transmission through
breastfeeding.
Vertical transmission, including BM transmission, is character-
ized by a transmission bottleneck [27–39]. In mother- to-child
transmission (MTCT), it has been suggested that this bottleneck is
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that are transmitted tend to be relatively insensitive to neutrali-
zation by maternal autologous antibodies (Abs), even in mothers
who harbor viruses with a range of neutralization sensitivi-
ties[32,39]. Consistent with the hypothesis that adaptive immunity
plays a role in MTCT, several studies comparing levels of
maternal plasma neutralizing antibody (NAb) titers reported that
transmitting (T) mothers have lower levels of NAb in plasma
compared to non-transmitting (NT) mothers [27,32,36–42]
suggesting that maternal NAb may contribute to protection of
the infant. However, the results of these studies are not consistent,
particularly with respect to a role for NAb in protection by
different routes of transmission [43–45]. Moreover, a recent study
of passive Absin 100 HIV-1 exposed infants did not find evidence
for a protective effect of broadly NAb on infant infection [46].
Until recently, most studies of BM HIV-1 Abs focused primarily
on determining the association between the levels or presence of
binding Abs to envelope (env) proteins and transmission. Several
studies that have focused on BM IgG and IgA have showed no
association between levels of these antibodies and transmission
[47,48]. Notably, infant infection status in these early studies was
determined by serology and/or clinical manifestation of AIDS, a
situation that could result in misclassification of infant infection
status. A more recent study that determined infant infection by
DNA PCR showed increased levels of BM IgA in T compared to
NT women suggesting that, rather than providing protection, BM
HIV-1 env specific soluable IgA, is associated with increased risk
of transmission [49]. However, all these studies used subtype B env
proteins, in some cases from lab adapted viruses to detect HIV-1
binding Abs despite being conducted in sub-Saharan Africa where
such variants are not typical of transmitted strains of HIV-1
[49,50]. Taken together, the results from BM binding studies have
not provided clear evidence of a role of BM Abs in vertical
transmission.
BM Abs could provide benefit by directly neutralizing the virus
within the milk or by non-neutralizing mechanisms such as
antibody dependent cellular cytotoxicity (ADCC)that target
infected cells. This could result in reduced levels of infectious
cell-free virus and BM infected cells, which are both correlates of
BM transmission [51–54]. The potential of Abs in BMto neutralize
HIV-1 and/or mediate ADCC has only very recently been
examined, and in this study of ARV-exposed, subtype C-infected
women in Malawi, NAbs were detected in about half of the BM
samples while ADCC activity was present in all BM samples
obtained at 1 month after delivery [55]. There have been no
studies to-date looking at BMS samples obtained from untreated T
and NT women, particularly in colostrum and early milk, which is
relevant given that virus levels are highest in colostrum [51]and
the majority of BM transmissions occur early in life [6,20]. There
has also been no study looking at how these BM Abs function in
relation to MTCT.
We evaluated neutralizing, binding and ADCC activity in BMS
or BMS-derived IgG and IgA and matched plasma from
antiretroviral (ARV) naı ¨ve T and NT mothers with high plasma
viral loads and systemic NAbs. Our data shows that BM Nabs are
rare and their levels are significantly lower than in plasma.
However, we report a high frequency of ADCC activity in BMS
that was significantly higher in NT women compared to T women.
These data suggest that BMADCC mediating Abs but not Nabs
may play a role in modulating HIV-1 transmission.
Materials and Methods
Study subjects and sample collection
Women enrolled in a randomized clinical trial comparing
breastfeeding to formula feeding in Nairobi Kenya provided BMS
samples used in this study [6]. Subjects received coded identifi-
cation numbers at the clinic and therefore BMS samples were
anonymous to laboratory personnel. The ethical review commit-
tees of the University of Nairobi, the University of Washington
and the Fred Hutchinson Cancer Research Center approved this
study and the Kenyan ministry of health gave permission for the
original study to be conducted. The methods for enrollment,
counseling and follow up have been described elsewhere [6,51].
Briefly, HIV-1 positive women were enrolled at 32 weeks gestation
and blood samples were taken for viral load and CD4 count
testing. Maternal blood, breast milk samples, and infant blood
samples were collected within the first week post-delivery, at 6
weeks, 14 weeks, 6 months and quarterly thereafter until 2 years.
Infant HIV-1 status was determined using DNA PCR [56]. Breast
milk samples were centrifuged to remove the lipid layer and the
supernatant was stored at 270uC before being shipped either on
dry ice or in liquid nitrogen to Seattle, Washington for long term
storage at 270uC until use. Plasma and BM viral loads were
determined using the Gen-Probe HIV-1 RNA assay (Gen-Probe,
La Jolla, Calf) [51,57]. Breastmilk samples used in this study were
chosen as the first available breastmilk sample after delivery for
each woman and the reported breastmilk viral loads are
contemporaneous.
Breast milk IgG Ab purification
BMS IgG was purified using NAb Protein G spin columns
(Pierce, Biotech, Rockford, IL), with minimal changes to the
manufactures instructions. Briefly, 250 ul of heat-inactivated BMS
was added to 250 ul of binding buffer and the mixture was added
to a protein G column followed by incubation at room
temperature (RT) with end over end mixing for 30 min.
Thereafter, the column was centrifuged to obtain the IgG flow
through (IgG stepFT) which was saved for subsequent IgA
purification. The column with bound Ab was washed 3 times
with 400 ul of binding buffer. Bound Ab was eluted with 1 ml of
elution buffer (pH 2.8) and the eluate was neutralized by adding
100 ul of 1 M Tris. HCl (pH 8.5). Thus, the final purified IgG Ab
was diluted 4-fold relative to the original BMS. The final eluted
IgG and IgA was retained at a 1:4 dilution of the original BMS
Author Summary
In the absence of intervention, only about one third of
infants born to HIV-1 infected mothers who are continu-
ously exposed to maternal breast milk over prolonged
periods get infected. This observation raises the possibility
that immune factors in infected women play a role in
limiting HIV-1 transmission. Identifying factors associated
with reduced HIV-1 transmission risk will improve our
understanding on the potential correlates of protection
that should be the focus of generating effective immuno-
gens and vaccination protocols. Here we assessed the
functional role of breast milk antibodies in a group of
women with high plasma viral loads and systemic NAbs
and determined that overall, breast milk contains low
levels of neutralizing antibodies when compared to
plasma. In contrast, we observed a robust non-neutralizing
activity in breast milk that was associated with infant
infection status. Our study adds to the growing evidence
of a potential role of non-neutralizing antibodies in
limiting HIV-1 transmission and calls for more attention
to this arm of the HIV-1 response.
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Coomassie blue staining (Simply Blue, Invitrogen) and ELISAs
using Human IgG ELISA kit (E-80G) and human IgA ELISA kit
(E-80A) (Immunology Consultants laboratory, Newberg, OR)
were used to confirm the purity of Ab fractions.
Breast milk IgA Ab purification
BMS IgA was purified from the IgG step FT using the method
outlined by Hirbod et.al with some modifications [58]. Spin
columns (Thermo) were packed with 400 ul of immobilized jacalin
(Pierce biotech, Rockford, IL) and washed 3 times with 400 ul of
PBS to equilibrate. The column was then loaded with 500 ul of the
IgG step FT and incubated on an end over end roller for 2 hours
at RT. After incubation, the column was centrifuged and a final
flow through (FT- fraction lacking IgG and IgA) was collected and
stored for analysis. The column was washed 3 times with PBS
followed by a 3-hour incubation with 500 ul of 1 M Melibiose to
elute bound IgA. The column was further washed with another
500 ul of elution buffer to maximize recovery and bring the final
dilution of purified IgA fraction to 1:4 relative to the original BMS,
similar to the IgG fraction. As before, coomassie staining and
ELISA were used to confirm the purity of Ab fractions.
Generation of HIV-1 Env genes and corresponding
pseudoviruses
The subtype A HIV-1 envQ461.d1 was cloned directly from
peripheral blood mononuclear cells (PBMCs) of a recently infected
Kenyan woman as described previously [59]. Autologous PBMC
and BM cell derived clones have either been previously described
or were obtained using the same protocol [39], in some cases with
modification of primers to allow amplification of the HIV-1
variant in that particular sample (primers are available upon
request). Plasmid DNA encoding the env of interest and a plasmid
encoding an env-deficient HIV-1 subtype A proviral DNA,
Q23Denv [60], were co-transfected into 293T cells at a 1:2 molar
ratio to generate pseudotyped viral particles as described [39,61].
Virus was harvested 48 hrs post-transfection and the infectivity
was determined by single round infection of TZM-bl cells as
described [39]. Pseudoviruses were also generated using Q23Denv
and simian immunodeficiency virus clone 8 (SIV) [62]orampho-
tropic murine leukimia virus (MuLV)envelope clones [63].
Neutralization assays
Neutralization was assessed by determining infection of a
reporter cell line, TZM-bl, as previously described [39]. Briefly,
500 infectious particles were incubated with 2-fold serial dilutions
of heat inactivated plasma or BMS, purified BMSIgG or IgA
fraction, FT fraction or media only in a total volume of 50 ul at
37uC for 1 hour. TZM-bl cells in 100 ul of growth medium
containing 30 ug/ml of diethylaminoethyl-dextran were then
added. After 48 hours, neutralization was determined by measur-
ing b-galactosidase activity present in the TZM-bl cell lysate. For
each virus/Ab combination, at least two independent experiments
were performed. Each experiment was performed intriplicate for
plasma and BMS or duplicate for purified BMSAb fractions.
Median inhibitory concentrations (IC50s) were defined as the
reciprocal dilution of plasma, BMS or purified antibody that
resulted in 50% inhibition, calculated by interpolation of the linear
portion of the neutralization curve on the log2 scale as previously
described [39,61]. Plasma and BMS samples were tested at 1:100
and 1:20 dilution respectively, while purified BMSAb fractions
were tested at 1:8 dilution (a 2-fold dilution of the recovered
purified fractions that were diluted 4 fold during processing). For
the purposes of analysis, in cases in which the IC50s were less than
the lowest dilutions tested, the midpoint value between the lowest
dilution and zero was assigned. IC50s from replicate experiments
were averaged by the geometric mean. Here IC50s indicate the
geometric mean IC50 estimates [64].
ELISAs for total and HIV-1 Env specific IgG and IgA
Human IgG ELISA kit (E-80G) and human IgA ELISA kits (E-
80A) (Immunology Consultants laboratory, Newberg, OR) were
used to determine the levels of total IgG and IgA in un-purified
BMS and plasma samples according to the manufacturer’s
instructions.
HIV-1env specific ELISAs were performed using the protocol
outlined by Sather et.al with minimal modifications [65]. Briefly,
Immulon 2HB ELISA plates were coated with 25 ng/well of a
HIV-1 subtype A Q461.d1 soluble trimeric gp140 protein purified
as described in [66] in 0.1 M NaHCO3, pH 9.4 overnight at room
temperature. Plates were blocked in phosphate buffered saline
(PBS), supplemented with 10% dry milk and 0.3% Tween-20 for
1h ra t3 7 uC. Unpurified BMS and plasma samples were diluted in
10% dry milk, 0.03% Tween in PBS. For detection of HIV-1env
specific IgG and IgA, BMS samples were diluted at 1:100 and
were titrated 2-fold up to a maximum dilution of 12,800. In cases
where an end point titer could not be determined at this dilution,
samples were diluted further up to a final dilution of 104,200. For
HIV-1 env specific plasma IgG, samples were diluted at 1:100,000
followed by a 2-fold titration up to a maximum dilution of
12,800,000 while for IgA samples were initially diluted 1:200
followed by a 2-fold dilution up to 25,600. Samples were loaded in
duplicate wells and incubated for 1 hr at 37uC. Plates were washed
in a plate washer and bound IgG Ab was detected at 37uC for 1 hr
with goat anti-human IgG- horseradish peroxidase (HRP) (Bio-
Rad, Hercules, CA) diluted 1:3000 while IgA was detected by goat
anti human IgA HRP(Invivogen, San Diego, CA) diluted 1:4000.
Plates were developed with 50 ul of 1-Step Ultra TMB-ELISA
solution (Pierce Biotech, Rockford. IL) and stopped with 50 ul 1 N
H2SO4. Absorption at 450 nm was read on an EL808 Ultra
Microplate Reader (Bio-TEK Instruments.inc). In this study, end
point titer (EPT) was defined as the BMS or plasma reciprocal
dilution at which the average OD value was greater than or equal
to two times the average OD value of background.
Rapid fluorescence-antibody dependent cellular
cytotoxicity assay (RF-ADCC)
The ability of BMS and their matched plasma to mediate
ADCC activity was determined as described by Gomez-Roman
et.al with a few modifications [67]. Briefly, CEM. NKr cells, a
natural killer resistant cell line (AIDS Research and Reference
Reagent Program, NIAID,NIH) were double stained with a
membrane dye, PKH-26(Sigma, St. Louis, MO, USA) and a
viability dye, carboxyfluorescein diacetate, succinimidyl ester
(CFSE) (Molecular Probes, Eugene, OR, USA) as recommended
by the manufactures. After staining, 1610
5 cells were coated for
1 hr at RT with 1.5 ug HIV subtype Agp120 protein obtained
from an infant in the Nairobicohortat 6 weeks post-infection
(BL035) [39]. Coated cells were then washed once and
resuspended in 1 ml of RPMI with 10%FBS. Five thousand
coated or uncoated CEM. NKr cells were added to the
appropriate duplicate wells containing 100 ul of 1:100 or 1:1000
heat inactivated BMS or plasma respectively. Similar experiments
were performed using media only or HIV IgG (NIH AIDS
Research, Germantown, MD, USA)as negative and positive
controls, respectively. The antibody-target cell mixture was
incubated at RT for 10 min to allow the antibody to interact
Breastmilk Antibodies and HIV-1 Transmission
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incubation, 50 ul of effector cells (HIV negative donor PBMCs)
were added to the mixture at an effector to target cell (E/T) ratio
of 50:1 and incubated for 4 hours at 37uC. For all 19 BMS and
plasma samples, PBMCs from the same donor were used in
parallel assays. Cells were then washed and fixed in 150 ul of 1%
paraformaldehyde-PBS and stored at 4uC overnight. Fixed cells
were analyzed within 24 hours of the ADCC assay using a BD
LSRII instrument (Becton Dickinson, San Jose, CA, USA). Flow
cytometry data was analyzed using Flojo version 9.4.6(Tree Star
Inc, Ashland, OR, USA). ADCC percent killing was defined as the
percentage of membrane labeled cells (PKH-26
+) that had lost
their viability dye (CFSE
2) after subtracting two times the level of
killing in the media only wells (background), as described in (67).
Statistical analysis
Odds ratios (OR) for assessment of associations between
detection of HIV-1 specific and non-specific activity in BMS and
transmission were estimated by Fisher’s Exact Test. IC50sfor HIV
positive and HIV negative controls were compared by one-sided t-
test on the log2 scale. All comparisons of Ab total concentrations
and HIV-1 env specific titers were based on paired t-tests on the
log10 scale, noting that differences on the log scale were
approximately normally distributed, and corresponding multivar-
iate adjustments were by linear regression. HIV-1 specific titers
among those with detected virus neutralization by BMS IgG and
IgA were each compared to titers among those with undetected
neutralization using Welch’s t-test on the log10 scale. All
correlations were measured by Pearson’s product moment
correlation coefficient (PPMCC), denoted r, with p-values based
on the Student’s t approximation for the distribution of the
corresponding standardized test statistic. The relationship between
maternal clinical correlates and BMS Ab neutralization, HIV-env
specific binding titers and ADCC activity were each individually
assessed by Welch’s t-test with corresponding adjusted estimates by
linear regression. Statistical analysis was performed using R 2.13
ISBN 3-900051-07-0 and STATA version 11 edition, (College
Station, TX).
Results
Characteristics of women in the study
The goal of this study was to determine the presence and
functional capacity of BM HIV-specific antibodies and to
determine if they impact MTCT. Therefore, we selected women
who had high plasma viral loads (greater than the cohort median
of 4.6 log10)and thus were at increased risk of transmission. Among
these women, we identified those who exhibited potent plasma
NAb responses (Majiwa and Overbaugh, unpublished data) to
maximize the chances of detecting BM NAbs. From this subset of
women, we selected those that breast-fed for greater than 3
months to capture cases of BM HIV exposure to the infant.
Women whose infants were HIV-1 positive before 6 weeks of life
were excluded to ensure that transmission was as a result of BM
and not late in-utero, or intra-partum exposure. An additional
criteria was that women had available BMS samples collected at
less than14 weeks after delivery because this early period is the
window within which the majority of BM transmissions occur [6]
and protein concentrations are highest [68,69]. Nineteen women
with a median CD4 count of 360 cells/uL met these criteria. The
median plasma and BM viral loads were5.22 and 2.44 log10
respectively, an ,2-log difference that was also observed in the
larger cohort [51]. Nine of these women transmitted HIV-1 to
their infants via BM at various time-points postpartum (Table 1).
Non-specific inhibition of viruses by BMS
The ability of heat inactivated BMS to neutralize virus bearing a
highly sensitive env variant isolated from a Kenyan woman soon
after her infection was determined. This heterologous HIV-1
subtype A env variant, Q461.d1, was chosen because .90% of
plasma from individuals in the region showed detectable
neutralization of this virus at a 1:100 plasma dilution [70]. The
results with plasma from 4 representative women are shown in
Figure 1A. All4 plasma samples neutralized Q461.d1 with IC50
values of ,500 or greater. Importantly, 50% inhibitory activity
was not achieved when testing plasma samples against SIV
suggesting that the neutralization response was specific to HIV-1.
Overall, virtually all19 plasmas displayed potent HIV-1 specific
neutralization, with IC50s ranging from 185 to 3144 (Table 1).
We could not detect HIV-1 neutralization in any of the BMS at
a similar starting dilution as plasma (1:100 data not shown). At a
very low starting dilution (1:4) there was substantial non-specific
inhibition of SIV and MuLV and preliminary assays suggested
potential cytotoxic effect of more concentrated BMS, as reported
previously [71]. BMS was therefore tested at a starting dilution of
1:20, hence 56more concentrated compared to plasma. Results
from BMS of 4 representative women against Q461.d1 and SIV
are shown in Figure 1B. While a low level of inhibition of HIV-1
was observed with some BMS such as MJ776 and MP199, there
was little difference in the magnitude of BMS neutralization of
Q461.d1 and SIV in all 4 cases. Among all 19 women, 9 BMSs - 6
from T and 3 from NT women - showed HIV-1 inhibition with
IC50 values ranging from 21–85; there was no detectable
inhibition by BMS from 3 T and 7 NT women. BMS from the
majority of women also inhibited SIV and MuLV pseudoviruses,
with IC50 values ranging from 20–95 (Table 1). A paired
comparison of BMS HIV-1 IC50s with the geometric mean of
IC50s for corresponding negative control viruses (SIV and
MuLV)showed that HIV-1 IC50s were not statistically greater
than those of the negative controls (p=0.44). This observation
suggested that the majority of inhibition we observed with BMS
was likely not due to HIV-1 specific Abs.
The presence of a non-specific inhibitor of HIV-1 in BMS could
nonetheless be relevant to transmission risk. We thus examined the
association between detection of non-specific activity and trans-
mission and found that this relationship was not statistically
significant (OR=4.77; 95% CI: 0.51, 71.53; p=0.17).
Limited ability of purified BMS IgG and IgA Abs to
neutralize heterologous virus
To determine what portion of the non-specific inhibition
observed with unfractionated BMS was due to Abs versus other
factors, we separately purified IgG and IgA Abs from BMS for use
in the neutralization assays. Bands of the expected sizes for IgG
and IgA were observed in the respective purified fractions by
coomassie staining and cross contamination between Ab isotype
fractions by total Ig ELISA was below detection (data not shown).
Purified Ab fractions were tested at a starting dilution of 1:8, which
translated to a dilution 2.5 times higher than the most
concentrated BMS we tested (1:20 dilution). Using the purified
BMS IgG fractions, neutralization of greater than 50%was
detected in only 2 (subjects MJ776 and MP199) of 19 purified
BMS IgG tested, with IC50s of 9.4 and 9.9 respectively. (These
two examples are shown in figure 2A and a summary of the 19 in
Table S1). Of these women MJ776 transmitted HIV-1 to the
infant while MP199 did not. In contrast, there was no detection of
neutralization by purified BMS IgA fractions tested (Results from
4 representative women are shown in figure 2B and a summary of
the 19 in Table S1). Importantly, purified BMS IgG and IgA
Breastmilk Antibodies and HIV-1 Transmission
PLoS Pathogens | www.plospathogens.org 4 June 2012 | Volume 8 | Issue 6 | e1002739fractions did not inhibit viruses pseudotyped with SIV env
including the two BMS IgG fractions from subjects MJ776 and
MP199, which had detectable neutralization of virus pseudotyped
with Q461.d1env (Figure 2A, B, and Table S1). The FT fraction,
which contained undetectable levels of BM IgG and IgA both by
ELISA and coomassie staining, (data not shown) retained the non-
specific activity displayed by BMS (Table S1).
Limited ability of purified BMS IgG and IgA Abs to
neutralize autologous blood and breast milk-derived
virus
To ensure that we were not missing NAb responses by using a
heterologous virus, we examined the ability of BMSAb fractions to
neutralize autologous virus in a subset of the 19 women. BMS IgG
and IgA Ab fractions and FT from a total of 8 women were each
tested against 2 pseudoviruses bearing autologous env variants
from blood [39]. Of the 8 women, 2 women both NTs, showed
low potency neutralization of the blood-derived autologous virus
to one of the two viruses tested. MM471 displayed low
neutralization potency with anIC50 of 15against one of her
autologous viruses when using IgG but not the IgA fraction
(representative experiment is shown in figure 3A). In contrast,
MA411 displayed low neutralization potency with an IC50 of 9
against one of the autologous virus with IgA but not with IgG
fractions (a representative experiment is shown in figure 3B). BMS
IgG and IgA fractions from the remaining six women, all Ts did
not neutralize their respective autologous viruses above 50%.
Autologous viruses for MJ776 and MP199 were not available for
testing
The ability of plasma and BMS purified Ab to neutralize
variants obtained from BM was also determined for two subjects
MF535 (T) and ML055 (NT). Autologous plasma from MF535
and ML055 diluted at 1:100 neutralized the respective BM viruses
withIC50s of 152 and 718, respectively. In contrast, there was no
detectable neutralization by BMAb fractions against these
autologous BM viruses (data not shown).
BMS IgG total and HIV-1 Env specific titers are lower than
plasma IgG
To determine if low NAbs in BMS reflected lower total BM Ab
levels, we measured the levels of total and HIV-1envspecific IgG
and IgA Abs in BMS and compared them to plasma (Figure 4).
The levels of total BMS IgG were 0.88 log10 lower than BMS
IgA(p,0.0001) (Figure 4A, black symbols). This is in contrast to
Table 1. The characteristics of transmitting and non-transmitting women in the study and the neutralization IC50s of their plasma
and BMS.
IC50s
Plasma
a BMS
b
ID Number
Viral
Subtype
CD4
Count
Log10
Plasma VL
c
Log10
BMS VL
c
Infant-
Infection Wk
d
Visit
Wk
e HIV
f SIV HIV SIV MLV
Transmitting MB885 A 136 4.78 1.93 6 0 535 50 85 83 95
Women MC046 A 255 5.05 3.17 6 0 1084 50 23 30 27
MF520 A 511 5.59 2.73 15 1 327 50 23 25 26
MF535 D 690 5.53 2.37 6 14 3144 50 21 10 10
MI206 A 262 5.12 2.27 6 0 751 50 22 10 24
MJ412 C 293 4.86 2.9 6 0 283 50 10 29 33
MJ613 A 104 5.64 2.96 6 1 751 50 10 10 24
MJ776 A 385 5.44 4.24 6 0 510 50 28 10 30
MM596 nd
g 392 5.75 2.26 6 6 469 50 10 10 10
Non-Transmitting MA411 A 416 5.5 2.76 na
h 0 1 2 0 0 5 03 83 33 8
Women MB727 C 416 4.70 2.54 na 8 314 50 10 10 10
MB807 A 217 4.78 3.62 na 0 989 50 10 10 10
MG540 A 285 5.6 3.95 na 0 762 50 37 27 22
MH230 A 651 5.02 2.79 na 14 647 50 22 10 10
MK371 D 352 4.62 bd
i na 2 354 50 10 10 10
ML055 D 213 5.18 2.76 na 0 1107 50 10 10 45
ML267 nd 551 5.68 3.77 na 0 185 50 10 10 10
MM471 A 360 5.26 3.36 na 8 1963 50 10 10 10
MP199 A 389 5.22 2.73 na 6 1253 50 10 10 28
aPlasma neutralization assays were performed at a starting dilution of 1:100; an IC50 of 50 was assigned in cases where 50% neutralization was not achieved.
bBMS neutralization assays were performed at a starting dilution of 1:20; an IC50 of 10 was assigned in cases where 50% neutralization was not achieved.
cViral Load.
dIndicates week since delivery when infant was first HIV-1 DNA positive.
eIndicates time-point after delivery at which BM sample was obtained.
fQ461.d1.
gNot done.
hNot applicable.
iBelow detection.
doi:10.1371/journal.ppat.1002739.t001
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than IgA (p,0.0001) (Figure 4A, grey symbols). There was a
pronounced difference between the magnitude of total IgG in
BMS and plasma with BMS total IgG being2.25 log10 lower than
plasma IgG (p,0.0001). In contrast, the total IgA levels in plasma
were only slightly higher than in BMS, with a modest 0.39log10
difference between BMS and plasma (p=0.004). We found
statistically significant correlation between total BMS IgG and
plasma IgG (r=0.67; p=0.0034)while the levels of BMS total IgA
correlated with total plasma IgA (r=0.78; p=0.0003). There was
no significant correlation between BMS total IgG and BMS total
IgA (r=0.39; p=0.10) (Table S2).
Next, we determined HIV-1 env specific IgG and IgA titers in
unfractionated BMS and plasma against soluble gp140 protein
derived from the subtype A variant, Q461.d1, that was used for
the neutralization studies (Figure 4B). HIV-1 env specific IgG titers
were obtained in 100% of BMS and plasma samples. In contrast,
HIV-1 env specific IgA titers were obtained in 50% of BMS and
90% of plasma samples; the rest were below the cut off value for
EPT as defined in this study. BMS HIV-1 env specific IgG titers
were 1.96 log10 higher compared to env specific IgA (p,0.0001)
(Figure 4B, black symbols). Similarly, HIV-1 env specific IgG titers
in plasma were higher by 3.63 log10 when compared to the env
specific IgA titers (p,0.0001) (Figure 4B, grey symbols). Overall,
similar to what we found for total IgG levels, BMS HIV-1 env
specific responses were 2.22 log10 lower compared to that in
plasma (p,0.0001) (Figure 4B). For HIV-1 env specific IgA, the
log10 difference between BMS and plasma was 0.59 (p=0.0004)
(Figure 4B). BMS HIV-1 env-specific IgG titers were correlated
with plasma HIV-1 env specific IgG titers (r=0.81; p,0.0001)and
BMS total IgG (r=0.76; p=0.0003). There was no statistically
significant correlation between BMS HIV-1 env specific IgG titers
and BMS HIV-1 env specific IgA (Table S2). Similar to BMS
HIV-1 env specific IgG titers and BMS total IgG, BMS HIV-1 env
specific IgA titers and BMS total IgA levels were also positively
correlated (r=0.69; p=0.015) (Table S2.)
We examined the relationship between the levels of HIV-1 env
specific titers in BMS and detection of neutralizing activity. The
three women with IgG neutralizing activity had a log10 IgG titer of
4.41 as compared to a mean of 3.83 among non-IgG-neutralizers
(p=0.0001). The one woman with IgA NAbs also had the highest
IgA env specific titer, which was1.10log10 greater than the group
median. (Figure. S1).
ADCC activity is common in BMS and it correlates with
HIV-1 env specific IgG titers
We determined the capacity of BMS binding antibodies and
their matched plasma to mediate ADCC. The appropriate BMS
and plasma dilution for the ADCC assay was determined by
testing serial 10-fold dilutions of 4 representative BMS and plasma
in the ADCC assay. The dilution that permitted detection of HIV-
specific ADCC activity above background levels, but did not yield
inhibition of ADCC activity that can occur with more concen-
trated samples [72] was chosen for testing (1:100 for BMS and
1:1000 for plasma). Using a single dilution also allowed us to test
all 19 BMS and plasma samples with effector cells obtained from a
single PBMC donor, which is critical for avoiding bias due to
differences in effector cell activity observed from donor to donor.
Figure 1. Neutralization potency of plasma and BMS from four mothers against heterologous virus. The graphs show percent
neutralization versus plasma (A) or BMS (B) dilution. Results using pseudovirus generated with heterologous Q461.d1 env (HIV-1 in black lines) are
shown in the left graph and with SIVMneCl8 (SIV in grey lines) are shown in the right graph. The corresponding symbol for the data from each of the
four mothers is shown in the upper right corner. The 50% neutralization level is shown with a dotted line. The results are from triplicate testing and
are representative of at least two independent experiments. The average IC50s for the two experiments for all 19 women is reported in Table 1.
doi:10.1371/journal.ppat.1002739.g001
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PLoS Pathogens | www.plospathogens.org 6 June 2012 | Volume 8 | Issue 6 | e1002739Figure 2. Neutralization potency of purified IgG and IgA from four mothers against heterologous virus. The graphs show percent
neutralization versus BMS purified IgG (A) or IgA (B) dilution. The corresponding symbol for the data from each of the four mothers is shown in the
upper right corner. Neutralization by IgG and IgA is represented by filled and open symbols, respectively. Results using pseudovirus generated with
Q461.d1 env (HIV-1 in black lines) are shown in the left graph and with SIVMneCl8 (SIV in grey lines) are shown in the right graph. The 50%
neutralization level is shown with a dotted line. The results are from duplicate testing and are representative of at least two independent
experiments. The average IC50s for the two experiments for all 19 women is reported in Table S1.
doi:10.1371/journal.ppat.1002739.g002
Figure 3. Neutralization potency of IgG and IgA from two mothers against autologous virus. Representative graphs showing percent
neutralization versus BMS purified IgG or IgA dilution. (a) Neutralization by IgG and IgA fractions from subject MM471 and (b) neutralization by IgG
and IgA fractions from subject MA411. IgG (filled square) and IgA (open square) responses against pseudovirus generated with autologous HIV-1 env
are shown in black lines and against SIVMneCl8 (SIV) are shown in grey lines. The 50% neutralization level is shown with a dotted line. The results are
from duplicate testing and are representative of at least two independent experiments.
doi:10.1371/journal.ppat.1002739.g003
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samples tested (Figures 5 A and B). BMS ADCC mediated killing
ranged from 1–27% (median,15%) while that of plasma ranged
from 16–36% (median, 24%). BMS ADCC activity was correlated
with gp140 env specific IgG titers (r=0.56, p=0.014) (Figure 6). A
log10 increase in gp140 titers was associated with an absolute
increase of 9.3 in % ADCC mediated killing by BMS (95% CI:
2.18, 16.41; p=0.013).
BMSADCC activity is associated with risk of infant
transmission
The relationship between maternal clinical correlates and BMS
Ab neutralization, HIV-env specific binding titers and ADCC
activity were each individually assessed. There was no statistically
significant association between antibody titers and any of the
clinical parameters examined. (Table S3).
There was no statistically significant association between
detection of NAbs and infant infection (OR=0.31; 95% CI:
0.0050, 4.94; p=0.58). We observed a trend for statistical
significance between infant infection and reduced BMSgp140
HIV-1 env specific IgG titers but not plasma titers (estimated
mean log10 difference 0.35 95% CI: 20.07, 0.77; p=0.098) in a
univariate analysis (Figure 7A). This association was in similar
direction after controlling for plasma viral load(p=0.038).
Importantly, NT women were more likely to have higher BM
ADCC activity compared to T women (estimated mean % killing
difference 6.89; 95% CI: 0.41, 13.37; p=0.039) (Figure 7B). This
relationship remained significant in a multivariate analysis
controlling for plasma viral load (p=0.011) and both plasma
and BM viral load (P=0.012). There was no association between
BM RNA viral load and BM ADCC activity (p=0.520) in these 19
women. There was also no significant difference between plasma
ADCC in T and NT women (Figure 7B).
Discussion
The potential of HIV-1 specific Absin BM to inhibit HIV-1 or
impact transmission risk has not been well defined. Despite the fact
that the levels of both IgG and IgA were low in BM compared to
plasma, we observed a trend for inverse correlation between the
levels of HIV-1 specific IgG and risk of infant infection in the 19
women examined here. The effect of these antibodies did not
appear to be through neutralization, as only 4 of 19 women had
any detectable neutralizing IgG or IgA Abs and there was no
correlation between detection of NAb and risk of infant infection.
Rather, the important functional activity of these antibodies was
linked to ADCC activity, as there was a statistically significant
inverse correlation between the levels of ADCC activity and risk of
infant infection. These data suggests that antibodies capable of
mediating ADCC may be one factor that impacts the risk of BM
HIV-1 transmission.
We found that BM HIV-1 env-specific IgG titers were
significantly higher than those of IgA but significantly lower when
compared to IgG from matched plasma samples. A reduced IgA
response at mucosal sites in HIV-1 infection is contrary to what is
observed with mucosal responses to other pathogens but consistent
with previous reports of a low HIV-1 specific binding IgA response
in favor of IgG at various mucosal sites [73–76]. In general, low
mucosal BM IgA might reflect an ability of HIV-1 to impair local
immune responses as a means of evading the humoral immune
system at the mucosal site. However, the observation that BM
HIV-1 env specific IgG titers were correlated with total plasma
IgG levels suggests that some of the BM IgG may originate from
systemic circulation, a process that could help fight infection at the
mucosal site.
Despite low HIV-specific antibody levels in BMS compared to
plasma, antibodies capable of ADCC were detected in all BMS
samples. We found that the capacity to mediate ADCC was
associated with the levels of HIV-1 env specific IgG titers, which is
in agreement with data from previous studies [55,77–79]. This is
perhaps not surprising given that envelope binding is a required
step for ADCC activity measured in the assay used here. Using
purified BMS antibodies from a subset of these women, we further
confirmed that ADCC activity in BM was exclusively mediated by
IgG (data not shown). Thus, IgG mediated ADCC can be detected
in unfractionated breastmilk, which includes IgA and other factors,
as well as with purified antibody. ADCC titers have previously
been shown to be generally higher compared to NAbs titers in the
same individual possibly due to the specificity required to
overcome the constraints posed by env protein in a bid to escape
neutralization and also the fact that virus neutralization requires
that all of the functional trimers be occupied by at least one
antibody [80,81]. Thus it may be possible to elicit high levels of
antibodies capable of ADCC using an HIV-specific immunogen
even in cases where neutralizing responses are limited.
BMS ADCC activity was significantly greater in NT compared
to T women, suggesting a possible role in impacting infant
infection. The mechanism by which BM ADCC might reduce
Figure 4. Levels of total and HIV-1 env specific IgG and IgA in
unfractionated BMS and plasma. (A)Total IgG and IgA in
unfractionated BMS and plasma. The Y-axis shows the log10 Ab conc
(ug/ml) and the X-axis shows the sample type and Ab isotype. Black and
grey symbols denote BMS and plasma, respectively. Triangles and
circles represent IgG and IgA, respectively. (B) Unfractionated BMS and
plasma HIV-1 env specific IgG and IgA titers. The Y-axis shows the log10
HIV-1 env specific titers (reciprocal dilution) and the X-axis shows the
sample type and Ab isotype. Symbols are as described for A.
doi:10.1371/journal.ppat.1002739.g004
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to lead to effective clearance of infected cells. Given that the levels
of HIV-infected cells in BM are correlated with transmission risk
[52], it is plausible that HIV-specific ADCC responses within BM
may act through reducing cell-associated viral transmission.
Other studies have implicated antibodies capable of ADCC in
providing protection from infection and/or controlling an
established infection. Several studies have shown that de novo
ADCC responses to HIV and SIV infection are correlated with
better viral control in chronic infection and/or clinical outcome.
[77,78,82–85]. Vaccine-induced ADCC responses have also been
correlated with reduced viral loads following SIV challenge
[78,79,86–88], supporting a potential role of Fc-mediated
antibody responses in blunting a new infection in SIV-infected
macaques. A study by Forthal et al. also provided evidence that
antibody-dependent cell-mediated virus inhibition, which is a
measure of ADCC in combination with other antiviral activities,
was correlated with infection rate in the Vax004 vaccine trial,
although ADCC alone was not directly examined in this study
[89]. In addition, studies of passive immunization using HIV
monoclonal antibodies in macaques suggest that FccR binding is
required for optimal protective efficacy [90]. These findings
support a potential role for antibodies that act through ADCC in
providing protection from infection in the non-human primate
model. The current study is the first that reports an association
between HIV-specific ADCC activity and risk of HIV infection in
humans.
This is the first study to examine BMS HIV-1 specific IgG and
NAbs in relation to transmission risk using a relevant HIV-1 env
representing recently transmitted virus from the dominant subtype
in the population. This may explain our ability to detect a trend in
association between binding antibodies and transmission, which
was not seen in prior studies using other env proteins less
representative of viruses in the study population to measure
binding [47,48].
We used the same highly neutralization sensitive (tier 1B)
subtype A HIV-1 env representing the dominant subtype in the
population under study to optimize our chances of detecting NAbs
in BMS. Importantly, plasma from all subjects had a potent NAb
response against this virus, indicating that all subjects had
generated NAbs capable of specifically recognizing this test virus.
Only 4 BMS had Abs that could neutralize .50% of either
Figure 5. ADCC activity in BMS and plasma. Percent ADCC activity in BMS(A) and plasma (B). BMS was tested at a 1:100 dilution and plasma at a
1:1000 dilution. The subject ID for the corresponding ADCC measure is shown below each bar. The results are from duplicate testing and are an
average of at least two independent experiments each done using effector cells from a single donor. nd indicates not done.
doi:10.1371/journal.ppat.1002739.g005
Figure 6. ADCC activity in relation to HIV-1 Env specific IgG
titers in BMS. The Y-axis shows % ADCC activity in BMS (1:100) and
the X-axis shows the log10 BM HIV-1 env specific IgG titers. Filled and
open symbols represent transmitting and non-transmitting women,
respectively. The trend line ‘Linear (ALL)’ is the regression line including
both transmitting and non-transmitting women.
doi:10.1371/journal.ppat.1002739.g006
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of HIV-1 specific NAbs was not associated with infant infection.
The neutralizing activity was observed in women with higher
levels of total IgG Abs in BMS. Therefore, it is possible that
generally low IgG and IgA titers in BM might explain the limited
neutralization capacity displayed by BM Abs.
The results of our study, showing low levels of HIV-1 env specific
NAbs inBMS, are consistent withanother recent study of BM HIV-
1 NAbs [55]. In this study of a NVP-treated, clade C infected
cohort, the levels of NAbs and HIV-1 env specific IgG were low in
BM collected at 4 weeks post-delivery compared to plasma. We
observed similarly low NAb levels in the breastmilk of ARV naı ¨ve
women in a cohort that was enrolled prior to the availability of
ARVs for prevention of MTCT [6]. Thus, collectively these studies
indicate that the level of HIV-1 specific NAb are low in both early
and mature milk, in both treated and untreated women and this is
true no matter the infecting HIV-1 subtype.
We detected non-specific inhibition of HIV-1 and unrelated
viruses (SIV, MLV) with several unfractionated BMS samples.
This observation is perhaps not surprising because innate factors
in BM such as defensins, lipids and lactofferin have documented
activity against many viruses including enveloped retroviruses [4].
The ability of unfractionated BMS to inhibit HIV-1 in the in vitro
TZM-bl assay used here did not correlate with risk of infant
infection.
There are several limitations to our study, most notably the fact
that we focused on a select group of women with high viral load
and systemic NAbs in order to optimize our chances of detecting
NAbs and to examine antibody levels in relation to transmission
risk. Thus it is unknown if these findings are applicable to women
with low viral loads or low systemic NAbs levels. Interestingly, a
correlation between ADCC activity and viral control in SIV-
infected macaques was only observed when animals with low viral
load were excluded [86]. These authors suggested that a threshold
of antigen may be needed to elicit robust ADCC. Certainly, larger
studies using relevant env antigens to examine HIV-1 specific BM
antibody responses in other populations will be needed to verify
these findings and determine if the findings apply to women with
lower viral levels and/or systemic NAb responses. In addition,
while we focused on breastmilk antibodies in relation to post-
partum transmission, there could be some misclassification of time
of infection in this study. Specifically, the cases of transmission
examined here were all cases of relatively early post-partum
transmission and we cannot exclude that some were the result of
intrapartum transmission, where BM antibody levels would be less
relevant. Finally, while we did not see an association between BM
viral RNA levels in this small study, but this does not rule out a
relationship between ADCC and the cellular viral reservoir.
Larger studies that include cell-associated virus levels and ADCC
activity will be needed to clarify this issue.
In conclusion, we found that the capacity of BM to neutralize
heterologous and autologous viruses obtained from blood and BM
is limited. This observation can be explained in part by the low
titers of Abs in BM compared to plasma in general, particularly
IgG. It is unclear if such low NAb levels could play a role in
protection, but no association was observed in this small study.
However, the association between HIV-1 env specific IgG titers
and ADCC activity with infant infection suggest that BM Ab could
be playing some role in modulating infection through non-
neutralizing mechanisms. To the best of our knowledge, this is the
first study to report a positive association between BM transmis-
sion and ADCC capacity in BM. If these results are verified in a
larger study of MTCT, then it would suggest that immunogens
tailored at enhancing BM Abs capable of ADCC might be of
potential benefit, particularly to HIV-1 infected women with high
viral loads, who are at the greatest risk of transmission.
Supporting Information
Figure S1 Levels of HIV-1 env specific IgG (Y-axis) and
IgA (X-axis) titers and detection of NAbs in BM. Circles
and squares represent transmitting and non-transmitting women,
respectively. Symbols filled with black and grey correspond to
detectable IgG and IgA neutralizing activity, while the open
symbols denote no detection. One point might represent one or
more values.
(TIF)
Table S1 Neutralization potency of purified BMS IgG,
IgA and FT. The table shows the neutralization potency of
purified BMS fractions from Transmitting (T) and Non-transmit-
ting (NT) mothers against heterologous HIV and SIV as a negative
control. Cases were assigned an IC50 value of ,4 when
neutralization was not detected.
(DOCX)
Figure 7. HIV-1 Env specific IgG titers and ADCC activity in BMS
in relation to infant infection. (A) Relation of HIV-1 gp140 specific
IgG titers and maternal transmission. Results are from duplicate testing
of unfractionated BMS and plasma and are an average of at least two
independent experiments. The Y-axis shows the log10 HIV-1 env specific
IgG titers (reciprocal dilution) and the X-axis shows the sample type
(BMS versus plasma) and HIV transmission status (NT versus T). (B) BMS
and plasma mediated ADCC activity in relation to transmission. The Y-
axis shows the % ADCC activity and the X-axis shows the sample type
and HIV transmission status. In both panels, triangles and circles
represent BMS and plasma, respectively while open and filled symbols
represented non-transmitting and transmitting women, respectively.
Results are from duplicate testing of unfractionated BMS and plasma
and are an average of at least two independent experiments.
doi:10.1371/journal.ppat.1002739.g007
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and HIV-1 env specific IgG and IgA in BMS and plasma.
Difference in levels (log10) indicates the average difference across the
19 women of the log10 levels for the first comparison measure minus
the second. Correlations are described by the Pearson correlation
coefficient, which indicates the strength of the linear association
between the two variables, on the log10 scale. Plasma and BMS
antibodies are correlated and lower levelswere observed in BMS than
in plasma. Env-specific IgG levels were greater than env-specific IgA.
(DOCX)
Table S3 Summary of the associations for antibody
levels and BM ADCC with clinical correlates of MTCT of
HIV-1. Estimates for each clinical correlate (maternal plasma
viral load, breastmilk viral load and CD4 count) correspond to the
estimated 10-fold change in the correlate with a unit increase in
the row-level variable. Units for ADCC were on the absolute
percentage scale, while units for all other variables were on the
log10 scale. No statistically significant associations were observed.
(DOCX)
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